Distinguishing Non-Small Cell Lung Adenocarcinoma Patients from Squamous Cell Carcinoma Patients and Control Individuals Using Serum Profiling

REFERENCES

• American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society, 2010. http://www.cancer.org/docroot/ STT/content/STT_1x_Cancer_Facts__Figures_2010.asp?from=fast
   Google Scholar
• Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulmon Med 2007;13:249–255.
   PubMed Web of Science ®Google Scholar
• Cooper WA, O'Toole SO, Boyer M, Horvath L, Mahar A. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology 2011;43:103–115.
   PubMed Web of Science ®Google Scholar
• Paech DC, Weston AR, Pavlakis N, Gill A, Rajan N, Barraclough H, Fitzgerald B, Van Kooten M. A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:55–63.
   PubMed Web of Science ®Google Scholar
• Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009;4:1202–1211.
   PubMed Web of Science ®Google Scholar
• Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34:1805–1811.
   PubMed Web of Science ®Google Scholar
• Richter R, Schuz-Knappe P, Schrader M, Ständker L, Jürgens M, Tammen H, Forssmann WG. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatog B Biomed Sci Appl 1999;726:25–35.
   PubMed Web of Science ®Google Scholar
• Chambers G, Lawrie L, Cash P, Murray GI. Proteomics: a new approach to the study of disease. J Pathol 2000;192:280–288.
   PubMed Web of Science ®Google Scholar
• Verma M, Wright GL Jr, Hanash SM, Gopal-Srivastava R, Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Annal NY Acad Sci 2001;945:103–115.
   PubMed Web of Science ®Google Scholar
• Hanas JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, Morgan DL, Denson KD, Prejeant KC, Gusev Y, Smith BJ, Hanas RJ, Postier RG, Brackett DJ. Biomarker identification in human pancreatic cancer sera. Pancreas 2008;36:61–69.
   PubMed Web of Science ®Google Scholar
• Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102–112.
   PubMed Web of Science ®Google Scholar
• Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51: 3–5.
   PubMed Web of Science ®Google Scholar
• West-Nørager M, Bro R, Marini F, Høgdall EV, Høgdall CK, Nedergaard L, Heegaard NH. Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. Anal Chem 2009;81:1907–1913.
   PubMed Web of Science ®Google Scholar
• Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271–284.
   PubMed Web of Science ®Google Scholar
• Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinform 2003;4:24.
   PubMed Web of Science ®Google Scholar
• Hocker JR, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Quillet AA, Hanas RJ, Peyton MD, Postier RG, Brackett DJ, Hanas JS. Distinguishing early clinical stages of pancreatic cancer using serum profiling. Cancer Invest 2011;29:173–179.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–1304.
   PubMed Web of Science ®Google Scholar
• Yang SY, Xiao XY, Zhang WG, Zhang LJ, Zhang W, Zhou B, Chen G, He DC. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 2005;5(83):1–7.
   PubMed Web of Science ®Google Scholar
• Hocker JR, Peyton MD, Lerner MR, Mitchell SL, Lightfoot SA, Lander TJ, Bates-Albers LM, Vu NT, Hanas RJ, Kupiec TC, Brackett DJ, Hanas JS. Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry. Lung Cancer 2011;74:206–211.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind C. International Union Against Cancer; TNM: Classification of Malignant Tumors, 6th edition. New York, NY: Wiley-Liss, 2002
   Google Scholar
• Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, McDonald JF, Fernández FM. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinform 2009;10:259–274.
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309–314.
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland M. Statistics notes: diagnostic tests 2: predictive values. BMJ 1994;309:102.
   PubMed Web of Science ®Google Scholar
• Altman DG, Bland M. Statistics notes: diagnostic tests 1: sensitivity and specificity. BMJ 1994;308:1552.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. User Evaluation of Precision Performance of Clinical Chemistry Devices. NCCLS Tentative Guideline EP5-T. Wayne, PA: NCCLS, 2004.
   Google Scholar
• Postier RG, Lerner MR, Lightfoot SA, Vannarath R, Lane MM, Hanas JS, Brackett DJ. DNA ploidy and Markovian analysis of neoplastic progression in experimental pancreatic cancer. J Histochem Cytochem 2003;51:303–309.
   PubMed Web of Science ®Google Scholar
• Jordana KW, Adkinsa CB, Sud L, Halpernb EF, Marka EJ, Christianic, DC, Chenga LL. Comparison of squamous cell carcinoma and adenocarcinoma of the lung by metabolomic analysis of tissue—serum pairs. Lung Cancer 2010;68:44–50.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004;22:2184–2191.
   PubMed Web of Science ®Google Scholar
• Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E, Fasanella S, Cuorvo LV, Palma PD, Rossi G, Papotti M, Pelosi G, Graziano P, Cavazza A, Denti MA, Barbareschi M. MiR-205 expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am Surg Pathol 2011;35:268–275.
   Web of Science ®Google Scholar